Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 16;16(6):1457-1458.
doi: 10.5114/aoms.2020.97411. eCollection 2020.

Tocilizumab in severe COVID-19

Affiliations

Tocilizumab in severe COVID-19

Nicola Lucio Liberato et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452. - PMC - PubMed
    1. Salvarani C, Bajocchi G, Mancuso P, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-217903. - DOI - PubMed
    1. D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with Coronavirus Disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “Hoit Spot”. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-217888. - DOI - PMC - PubMed
    1. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–5. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42. - PubMed